Pharma Blog Watch

P&G Ulcerative Colitis Drug (The Pharm Voice)
In her blog, Gloria Gamat reports that Procter & Gamble (P&G) has presented data from clinical trials that "revealed that the success of treatment is associated with mucosal healing in patients with moderately active ulcerative colitis (UC) who received either 2.4 or 4.8 grams of mesalamine per day." Mesalamine, or Asacol, is "indicated for the treatment of mildly to moderately active UC."